Ausio Pharmaceuticals LLC
This article was originally published in Start Up
Executive Summary
Ever since the disturbing news broke about the health risks of HRT, drug and vitamin manufacturers have been angling to develop their own products as alternatives. Ausio Pharmaceuticals' candidate is S-equol, a synthetic form of a metabolite found in soy beans that is produced when an isoflavone known as daidzein is broken down by a certain kind of bacteria. Individuals who possess the bacteria and who frequently consume soy products have been shown to have a lower incidence of cardiovascular diseases, menopausal symptoms and certain cancers. Ausio is betting that S-equol can be developed as a pharmaceutical product capable of passing muster with the FDA and other regulatory agencies.